GlassScriptPhysician profile
Kirsy Japa
NPI 1558864678
$886.07
in general payments reported to CMS, 2019-2025
9 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.41 · 2020: $165 · 2021: $48.49 · 2022: $131 · 2023: $225 · 2024: $84.02 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $245.60 | 2022-2025 | Vivitrol, Aristada, Lybalvi |
| Allergan, INC. | $166.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $162.47 | 2024-2025 | Invega |
| Otsuka America Pharmaceutical, INC. | $130.66 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Viiv Healthcare Company | $96.32 | 2023 | Cabenuva |
| Abbvie INC. | $38.74 | 2021-2023 | |
| Janssen Scientific Affairs, LLC | $19.39 | 2024 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.31 | 2025 | Caplyta |
| Tris Pharma INC | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirsy Japa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.